Literature DB >> 24322015

Assessment of CD105, α-SMA and VEGF expression in gastric carcinomas.

Diana Grigore1, Cristiana Eugenia Simionescu, A Stepan, Cl Mărgăritescu, Maria Bălăşoiu, C C Georgescu, Daniela Cernea, Daniela Dumitrescu.   

Abstract

In this study, we analyzed the microvessel density (MVD) for CD105+ and α-SMA+ vessels and the VEGF immunoexpression in 38 gastric carcinomas. CD105+ MVD had superior values at the advancing edge compared with the intratumoral area, no matter of the analyzed clinico-pathological parameters, the difference being significant only in intestinal type, moderate differentiated carcinomas as well as in T2-T3 carcinomas, without lymph node metastases (p<0.05). Intratumoral expression of CD105+ MVD indicated significant differences related to histological type (p=0.006), depth of invasion (p=0.027) and lymph node metastases (p=0.009), but without statistical association in case of the advancing edge or metastases. The assesses of α-SMA+ MVD indicated no differences between intratumoral and advancing edge areas, no matter of the analyzed parameters, excepting intestinal type carcinomas, which presented significant high values (p=0.003) at the advancing edge. VEGF score revealed significant differences related to histological type (p=0.020), differentiation degree of the intestinal type carcinomas (p=0.036) and depth of invasion (p=0.049). In case of metastases, the levels of VEGF expression were higher in the primary tumor, without statistically significant differences (p>0.05). It were significant differences of intratumoral VEGF expression depending on CD105+ MVD values (p=0.019), but not with α-SMA+ MVD (p>0.05). Angiogenesis evaluated through the VEGF and MVD (CD105+ and α-SMA+) expression is correlated with the progression and metastasis of gastric cancer and could be considered a prognostic marker of these tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24322015

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  7 in total

Review 1.  New advances in targeted gastric cancer treatment.

Authors:  Daniela Cornelia Lazăr; Sorina Tăban; Marioara Cornianu; Alexandra Faur; Adrian Goldiş
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 2.  Personalised Treatment in Gastric Cancer: Myth or Reality?

Authors:  Noelia Tarazona; Valentina Gambardella; Marisol Huerta; Susana Roselló; Andrés Cervantes
Journal:  Curr Oncol Rep       Date:  2016-07       Impact factor: 5.075

3.  Parameters of dynamic contrast-enhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer.

Authors:  Lin Li; Kai Wang; Xilin Sun; Kezheng Wang; Yingying Sun; Guangfeng Zhang; Baozhong Shen
Journal:  Med Sci Monit       Date:  2015-02-01

Review 4.  Molecular targeted therapy for the treatment of gastric cancer.

Authors:  Wenting Xu; Zhen Yang; Nonghua Lu
Journal:  J Exp Clin Cancer Res       Date:  2016-01-04

5.  Association between spectral computed tomography images and clinicopathological features in advanced gastric adenocarcinoma.

Authors:  Xiaohua Chen; Ke Ren; Pan Liang; Jiayin Li; Kuisheng Chen; Jianbo Gao
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

6.  Immunohistochemical Expression of Epithelial-Mesenchymal Transition Markers in Early Gastric Cancer: Cancer Tissue versus Noncancer Tissue.

Authors:  Hee Jae Jung; Su Jin Hong; Shin Hee Kim
Journal:  Clin Endosc       Date:  2019-05-22

7.  Identification of CD105+ Extracellular Vesicles as a Candidate Biomarker for Metastatic Breast Cancer.

Authors:  Sasha R Douglas; Kay T Yeung; Jing Yang; Sarah L Blair; Olga Cohen; Brian P Eliceiri
Journal:  J Surg Res       Date:  2021-07-24       Impact factor: 2.192

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.